120173-57-1

• 常用中文名：N-芴甲氧羰基-O-(2-乙酰氨基-3,4,6-三-O-乙酰基-2-脱氧-α-D-吡喃半乳糖基)-L-丝氨酸
• 常用英文名：Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH
• CAS号：120173-57-1
• 分子式：C₃₂H₃₆N₂O₁₃
• 分子量：656.63400
• 相关类别： 生物化工 氨基酸及其衍生物 丝氨酸类衍生物
• 发布时间：2018-12-24 09:18:07
• 更新时间：2026-06-30 13:13:23
• Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH 是一种抗肿瘤药物。

名称

• 中文名: N-芴甲氧羰基-O-BETA-(2-乙酰氨基-2-脱氧-3,4,6-三-O-乙酰基-ALPHA-D-吡喃半乳糖基)-L-丝氨酸
• 英文名: (2S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
• 中文别名: N-芴甲氧羰基-O-(2-乙酰氨基-3,4,6-三-O-乙酰基-2-脱氧-Α-D-吡喃半乳糖基)-L-丝氨酸; N-芴甲氧羰基-O-BETA-(2-乙酰氨基-2-脱氧-3,4,6-三-O-乙酰基-Α-D-吡喃半乳糖基)-L-丝氨酸; 化合物：Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH); (S)-2-((((9H-芴-9-基)甲氧基)羰基)氨基)-3-((((2S,3R,4R,5R,6R)-3-乙酰氨基-4,5-二乙酰氧基-6-(乙酰氧基甲基)四氢-2H-吡喃-2-基)氧基)丙酸; 化合物:Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH (Fmoc-Ser-(GalNAc(Ac)3-alpha-D)-OH); N-FMOC-O-(2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-Α-D-GALACTOPYRANOSYL)-L-SERINEN-芴甲氧羰基-O-(2-乙酰氨基-3,4,6-三-O-乙酰基-2-脱氧-Α-D-吡喃半乳糖基)-L-丝氨酸; Tn抗原: Fmoc-Ser(GalNAc(Ac)3-α-D)-OH; N-芴甲氧羰基-O-(2-乙酰氨基-2-脱氧-3,4,6-三-O-乙酰基-ALPHA-D-吡喃半乳糖基)-L-丝氨酸; 半乳糖胺L-丝氨酸; TN抗原(丝氨酸,FMOC,过乙酰化)
• 英文别名: FMOC-L-SER(ALPHA-D-GALNAC(AC)3)-OH; N-Fmoc-O-beta-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-alpha-D-galactopyranosyl)-L-serine; OVN73571; N-Fmoc-O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl)-L-serine; FMOC-SERINE(GALNAC(AC)3-ALPHA-D)-OH; Fmoc-Ser(GalNAc(Ac)-α-D)-OH; Fmoc-Ser(GalNAc(Ac)3-a-D)-OH; N-a-FMoc-O-b-(2-acetaMido-2-deoxy-3,4,6-tri-O-acetyl-a-D-galactopyranosyl)-L-serine; N-Fmoc-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-|A-D-galactopyranosyl]-L-serine; (2S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-2-(9H-fluoren-9-ylmethoxycbonylamino)propanoicaci; N-FMOC-O-(2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-ALPHA-D-GALACTOPYRANOSYL)-L SERINE; Fmoc-Ser(a-D-GalNAc(Ac)3)-OH; FMOC-SER(GALNAC(AC)3-ALPHA-D)-OH; Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH, 10 mM in DMSO; N-Fmoc-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-Alpha-D-galactopyranosyl]-L-serine; Fmoc-Ser(Ac3AcNH-α-Gal)-OH Novabiochem; Fmoc-Ser(α-D-GalNAc(Ac)3)-OH; 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-a-D-galactopyranosyl-Fmoc serine; FMoc-Ser(2-acetaMido-3,4,6,-tri-O-acetyl- 2-deoxy-α-D-galactopyranosyl)-OH; FMoc-Ser-(Ac3AcNH-α-Gal)-OH; Fmoc-L-Ser(TnAc4)-OH,N-alpha-(9-fluorenylmethyloxycbonyl)-O-(2-acetamido-2deoxy-3,4,6-tri-O-acetyl-alpha-D-galactopyr; 3-{[4,5-BIS(ACETYLOXY)-6-[(ACETYLOXY)METHYL]-3-ACETAMIDOOXAN-2-YL]OXY}-2-{[(9H-FLUOREN-9-YLMETHOXY)C; N-α-Fmoc-O-β-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-α-D-galactopyranosyl)-L-serine; N-ALPHA-FMOC-O-BETA-(2-ACETAMIDO-2-DEOXY-3,4,6-TRIO-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL)-L-SERINE; Fmoc-Ser(α-D-Gal- NHAc(Ac)3)-OH; Fmoc-L-Tnser-OH; Fmoc-Ser-(Ac3AcNH-|A-Gal)-OH; Tn Antigen: Fmoc-Ser(GalNAc(Ac)3-α-D)-OH; N-Fmoc-O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl)-L-serine; N-alpha-(9-Fluoroenylmethyloxycbonyl)-o-(2-acetamido-2deoxy-3,4,6-tri-o-acetyl-alpha-d-galactopyranosyl)-l-serine; N-alpha-Fmoc-O-beta-(2-acetamido-2-deoxy-3,4,6-tri; (2S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-2-(9H-fluoren-9-ylmethoxycbonylamino)propanoic acid; N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-|A-D-galactopyranosyl]-L-serine; 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranosyl-Fmoc serine; FMOC-SER(AC3ACNH-ALPHA-GAL)-OH; Fmoc-Ser[GalNAc(Ac)3-α- D ]-OH; Fmoc-Ser(2-acetamido-3,4,6,-tri-O-acetyl-2-deoxy-|A-D-galactopyranosyl)-OH; Fmoc-L-Ser(TnAc4)-OH, N-alpha-(9-Fluorenylmethyloxycbonyl)-O-(2-acetamido-2deoxy-3,4,6-tri-O-acetyl-alpha-D-galactopyranosyl)-L-serine; N-ALPHA-FMOC-O-(2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL)-L-SERINE; β-L-Altropyranoside,(2S)-2-cboxy-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl2-(acetylamino)-2-deoxy-,3,4,6-triacetate; N-Fmoc-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl]-L-serine; N-[(9H-Fluoren-9-ylMethoxy)carbonyl]-O-[3,4,6-tri-O-acetyl-2-(acetylaMino)-2-deoxy-α-D-galactopyranosyl]-L-serine; FMOC-L-SER(TNAC4)-OH; Fmoc-Ser(GalNAc(Ac)3-α-D)-OH; L-Serine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl]; N-ALPHA-(9-FLUORENYLMETHYLOXYCBONYL)-O-(2-ACETAMIDO-2DEOXY-3,4,6-TRI-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL)-L-SERINE; GALNAC L-SERINE; N-ALPHA-(9-FLUORENYLMETHOXYCBONYL)-O-BETA-(2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL)-L-SERINE; Fmoc-L-Ser(α-D-GalNAc(Ac)3)-OH; N-ALPHA-FMOC-O-BETA-(2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL-ALPHA-D-GALACTOPYRANOSYL)-L-SERINE; GalNAc-Ser; Fmoc-Ser(Ac3GalNAcα)-OH

物化性质

• 分子式: C₃₂H₃₆N₂O₁₃
• 分子量: 656.63400
• 精确质量: 656.22200
• PSA: 202.09000
• LogP: 2.43280
• 外观性状: 白色粉末
• 储存条件: -15°C

生物活性

• 描述: Fmoc-Ser(O-α-D-GalNAc(OAc)3)-OH 是一种抗肿瘤药物。
• 相关类别:
  信号通路 >> 其他 >> 其他
  研究领域 >> 癌症
• 参考文献:

  [1]. Jorg Eberling, et al. Chemoselective Removal of Protecting Groups from O-Glycosyl Amino Acid and Peptide (Methoxyethoxy)ethyl Esters Using Lipases and Papain. J. Org. Chem., 1996, 61 (8), pp 2638–2646

安全

• 危险品运输编码: NONH for all modes of transport

合成路线

上下游产品

上游产品  7
120204-22-0 67673-39-6 100929-00-8 136497-88-6
28920-43-6 83956-40-5 213331-74-9
下游产品  0